The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / European Beacon for Rheumatology

European Beacon for Rheumatology

January 1, 2008 • By Gretchen Henkel

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Dr. Smolen
Dr. Smolen

In his medical school days, Josef S. Smolen, MD, was already revealing himself as a “glass half full” kind of person. As proof, consider the following anecdote:

You Might Also Like
  • Comparative Assessment of the Different ACR/EULAR Remission Definitions for RA for Their Use as Clinical Trial End Points
  • Letters to the Editor
  • A Regulatory Leader in Rheumatology
Explore This Issue
January 2008
Also By This Author
  • Lupus Classification Criteria Expanded; Treat-to-Target Approach Gains Support

“When I selected rheumatology,” Dr. Smolen recalls with a slight chuckle, “my colleagues in nephrology, cardiology, and endocrinology asked me why I was so crazy to select an area where so little could be done.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“My answer to them was: a) if little could be done, that would be changed; and b) that this was an area where research could be performed yielding more information on pathogenesis and one might be able to find new remedies.”

Dr. Smolen sensed that rheumatology would offer opportunity not only for investigation, but also for helping to reduce burden on patients. “Where there is a lot of burden, even relatively small reductions may mean a lot to the people who are affected,” he says. In the three decades since he completed medical school, Dr. Smolen’s inherent optimism and tireless investigations have yielded important intellectual advancements in the field of rheumatology.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Smolen is chair of the division of rheumatology at the Medical University of Vienna in Austria and chair of the second department of medicine at the Center for Rheumatic Diseases at Hietzing Hospital in Vienna. He has published over 200 papers in rheumatology and immunology and is perhaps best known for his group’s work on revealing novel pathogenic insights pivotally involved in the evolution of new treatments for RA, such as leflunomide and biologic agents. He is also known for his new look at outcomes in RA, especially the development of the Simplified and the Clinical Disease Activity Indices (SDAI and CDAI), the latter in close collaboration with Daniel Aletaha, MD, a rheumatology fellow at the Medical University of Vienna.

Dr. Smolen has established his department as an important center in the international rheumatology community, helping to usher in huge leaps in our understanding of the disease, as well as advancing treatment improvements. “Josef has been a beacon of the development of informed, scientifically based rheumatology in Europe,” says Peter E. Lipsky, MD, chief of the autoimmunity branch of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in Bethesda, Md., and a long-time colleague of Dr. Smolen.

Dr. Smolen (bottom left, white shirt) with his rheumatology colleagues at a recent retreat.
Dr. Smolen (bottom left, white shirt) with his rheumatology colleagues at a recent retreat.

Fascinated by Immunological Problems

Dr. Smolen says that, for him, the choice of rheumatology was a natural one. As a medical student, he was fascinated by immunological problems and autoimmune diseases, which were not well understood in the late 60s and early 70s when he attended the University of Vienna. After receiving his MD in 1974, he followed his interests in immunological disease and became a fellow at the university’s Institute of Immunology, studying under his mentor, Professor Carl Steffen.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Practice Management, Professional Topics, Profiles Tagged With: Career, Immunology, Metrics, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), rheumatology, TrainingIssue: January 2008

You Might Also Like:
  • Comparative Assessment of the Different ACR/EULAR Remission Definitions for RA for Their Use as Clinical Trial End Points
  • Letters to the Editor
  • A Regulatory Leader in Rheumatology
  • Similar RA Outcomes with Abatacept & Tocilizumab

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.